Lyka Labs P/E Ratio
Lyka Labs (LYKALABS) P/E ratio is not applicable — EPS (TTM) ₹-2.81, 2 consecutive loss quarters. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company has reported losses in the last 2 quarters. P/E ratio is not applicable during loss periods.
Consecutive Loss Quarters: 2
Current EPS: ₹-2.81
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | -2.13 | -8 | Loss |
| Sept 2025 | -0.94 | -3 | Loss |
| Mar 2025 | 0.49 | 2 | Profit |
| Jun 2025 | 0.25 | 1 | Profit |
| Sept 2024 | 0.58 | 2 | Profit |
| Mar 2024 | -3.83 | -2 | Loss |
| Jun 2024 | 0.40 | 1 | Profit |
| Dec 2024 | 0.75 | 3 | Profit |
Healthcare Peers with Valid P/E Ratios — LYKALABS Comparison
Healthcare sector average P/E 55.26, median 31.04 — LYKALABS excluded (negative EPS).
Sector Average PE
55.26
Sector Median PE
31.04
Lowest PE
2.86
Profitable Companies
195
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.65 | ₹29 | Low |
| Phaarmasia | PHRMASI | 3.84 | ₹68 | Low |
| JFL Life Sciences | JFLLIFE | 4.64 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.69 | ₹7,502 | Low |
| Shelter Pharma | SHELTER | 5.32 | ₹50 | Low |
| Mono Pharmacare | MONOPHARMA | 6.02 | ₹19 | Low |
| Royal Sense | ROYAL | 7.4 | ₹51 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹79 | Low |
| Amwill Health Care | AMWILL | 7.71 | ₹88 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see LYKALABS share price screener.
- Read LYKALABS dividend payout details for the complete payout history and dividend yield track record.
- See Lyka Labs P/B ratio trends to compare market price against book value per share.